Skip Nav Destination
![]()
You do not currently have access to this content.
HER2-Targeted Agents Potential First Treatments for NSCLC
September 10, 2024
Two HER2-targeted tyrosine kinase inhibitors, BAY 29270078 and zongertinib, each showed robust efficacy and safety in early phase. Patients experienced significant tumor shrinkage rates, and the incidence of serious adverse events was low in both trials.
RSS Feeds